A new phase IIb readout at odds with earlier data suggesting PTI-125 would diminish key biomarkers of neuroinflammation and neurodegeneration in Alzheimer’s patients has left Cassava Biosciences Inc. President and CEO Remi Barbier looking for answers.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amarin, Astellas, Caladrius, Cassava, Contrafect, Exicure, Ferring, Gesynta, Implicit, Merck, Mersana, Orchard, Orexo, Pfizer, Roche, Samsung, Trillium, Ultragenyx, Urogen, VBI, Venatorx.

Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) leapt 36% higher to $42.12 on Thursday after limited data from a small number of relapsed/refractory (r/r) non-Hodgkin lymphoma patients showed a combination of the company's anti-CD19 allogeneic CAR T candidate, ALLO-501, and an anti-CD52 monoclonal antibody, ALLO-647, met with an overall response rate of 78%.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Advaxis, Argenx, Bioxcel, Capricor, Diamedica, Frequency, Galmed, Hookipa, Horizon, Incyte, Kaleido, Krystal, LG Chem, Morphosys, Pfizer, Phoenix Tissue Repair, Regentree, Relief, Tolero, Ultragenyx, Viela, X4.

Despite evidence of efficacy in binge-eating disorder (BED), Sunovion Pharmaceuticals Inc.'s dasotraline's second lease on life is done, for now. Following an initial plan to discontinue the asset in a 2010 portfolio reshuffle, the drug is now being shelved due to the need for additional clinical studies on its benefit-risk profile, parent Sumitomo Dainippon Pharma Co. Ltd. said.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actelion, Alexion, Avrobio, Biogen, Capricor, Curis, Fulcrum, Gossamer, I-Mab, Medday, Novadip, Novartis, Novo, Opiant, Roivant.